The effect of lupus anticoagulant in the second-generation assay for activated protein C resistance

American Journal of Clinical Pathology

Volumn 119, Issue 1, 2003, Pages 66-71

  Ragland, Brian D ^a   Reed, Cari E ^a   Eiland, Barbara M ^a   Tichenor, Patricia H ^a   Hudson, Christine L ^a   Fritsma, George A ^a   Adler, Brian K ^a   Marques, Marisa B ^a  

^a West Pavilion ^*

Author keywords

APCR ratio; Factor V Leiden; Lupus anticoagulant; Modified activated protein C resistance (APCR) assay

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; DNA; LUPUS ANTICOAGULANT; BLOOD CLOTTING FACTOR 5;

ADULT; ARTICLE; CASE REPORT; DISEASE PREDISPOSITION; FEMALE; GENE MUTATION; HUMAN; HYPERCOAGULABILITY; LABORATORY TEST; PATIENT REFERRAL; PRIORITY JOURNAL; SPONTANEOUS ABORTION; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; ACTIVATED PROTEIN C RESISTANCE; ANALYTICAL EQUIPMENT; BLOOD; BLOOD CLOTTING TEST; EVALUATION; LABORATORY DIAGNOSIS; MASS SCREENING; METHODOLOGY; PHYSIOLOGY; PREDICTION AND FORECASTING; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ACTIVATED PROTEIN C RESISTANCE; ADULT; BLOOD COAGULATION TESTS; FACTOR V; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; MASS SCREENING; PREDICTIVE VALUE OF TESTS; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 85047688944     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/1GN6NTM7BQAP8VKX     Document Type: Article

References (14)

1. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004-1008.
2. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
3. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344:1222-1231.
4. Zöller B, Svensson PJ, He X, et al. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994;94:2521-2524.
5. Dahlbäck B. Resistance to activated protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis: functional tests and DNA-based assays: pros and cons. Thromb Haemost. 1995;73:739-742.
6. Marques MB, Triplett DA. When to suspect hypercoagulability and how to investigate it. Ann Diagn Pathol. 2001;5:177-183.
7. Legnani C, Palareti G, Biagi R, et al. Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation. Br J Haematol. 1996;93:694-699.
8. Goualt-Heilmann M, Leroy-Matheron C. Factor V Leiden-dependent APC resistance: improved sensitivity and specificity of the APC-resistance test by plasma dilution in factor V-depleted plasma [letter]. Thromb Res. 1996;82:281-283.
9. Tripodi A, Negri B, Bertina RM, et al. Screening for the FV:Q506 mutation: evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis. Thromb Haemost. 1997;77:436-439.
10. Triplett DA. Lupus anticoagulants/antiphospholipid protein antibodies: the great imposters. Lupus. 1996;5:431-435.
11. Brandt JT, Triplett DA, Alving B, et al. Criteria for the diagnosis of lupus anticoagulant: an update. Thromb Haemost. 1995;74:1185-1190.
12. Benattar N, Schved JF, Biron-Andreani C. A new dilution for the modified APTT-based assay for activated protein C resistance: improvement of the reliability in patients with a lupus anticoagulant. Thromb Haemost. 2000;83:967-968.
13. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999;353:1167-1173.
14. Svennson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517-522.